0000950170-23-007971 Sample Contracts

CONSULTANCY LETTER AGREEMENT
Consultancy Letter Agreement • March 15th, 2023 • iTeos Therapeutics, Inc. • Biological products, (no disgnostic substances)

This consultancy letter agreement (the "Agreement") confirms your engagement by ITEOS as a consultant for ITEOS, as of the Effective Date set forth above, to perform certain services as may be agreed in writing from time to time as set forth below (collectively, the "Services").

AutoNDA by SimpleDocs
Amendment No. 2 to Collaboration and LICENSE AGREEMENT
Collaboration and License Agreement • March 15th, 2023 • iTeos Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 2 (“Amendment No. 2”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) and previously amended on January 24, 2022, between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”), and iTeos Belgium S.A., a public limited company having an office at Rue des Frères Wright, 29, B-6041 Gosselies Belgium (“ITEOS”) is effective as of September 30, 2022 (“Amendment Effective Date”). Each of GSK and ITEOS may be referred to herein as a “Party” and together, the “Parties.”

Amendment No. 1 to Collaboration and LICENSE AGREEMENT
Collaboration and License Agreement • March 15th, 2023 • iTeos Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Amendment No. 1 (“Amendment No. 1”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”), and iTeos Belgium S.A., a public limited company having an office at Rue des Frères Wright, 29, B-6041 Gosselies Belgium (“ITEOS”) is effective as of January 24, 2022 (“Amendment Effective Date”). Each of GSK and ITEOS may be referred to herein as a “Party” and together, the “Parties.”

Informal translation from the original French ADDENDUM TO THE EMPLOYMENT CONTRACT
iTeos Therapeutics, Inc. • March 15th, 2023 • Biological products, (no disgnostic substances)
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!